Cim, LLC Genmab A/S Transaction History

Cim, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 17, 2024	BUY	$35.27 - $42.24 $6,666 - $7,983	189 Added 0.78%	24,268 $855,000
Q2 2023 May 17, 2024	BUY	$37.4 - $42.94 $900,554 - $1.03 Million	24,079 New	24,079 $915,000
Q1 2023 May 17, 2024	BUY	$34.88 - $43.22 $939,667 - $1.16 Million	26,940 New	26,940 $1.02 Million
Q4 2022 Feb 10, 2023	SELL	$33.8 - $47.06 $106,098 - $147,721	-3,139 Reduced 10.46%	26,877 $1.14 Million
Q3 2022 Nov 02, 2022	SELL	$31.52 - $373.61 $1,544 - $18,306	-49 Reduced 0.16%	30,016 $1.15 Million
Q2 2022 Jul 11, 2022	BUY	$26.83 - $38.57 $55,564 - $79,878	2,071 Added 7.4%	30,065 $1.03 Million
Q1 2022 Apr 12, 2022	BUY	$30.95 - $39.68 $14,391 - $18,451	465 Added 1.69%	27,994 $1 Million
Q4 2021 Jan 26, 2022	SELL	$35.87 - $47.12 $140,753 - $184,898	-3,924 Reduced 12.48%	27,529 $897,000
Q3 2021 Nov 08, 2021	BUY	$41.55 - $48.72 $31,993 - $37,514	770 Added 2.51%	31,453 $1.46 Million
Q2 2021 Aug 09, 2021	BUY	$32.88 - $44.57 $5,852 - $7,933	178 Added 0.58%	30,683 $1.4 Million
Q1 2021 May 11, 2021	BUY	$30.92 - $44.4 $38,866 - $55,810	1,257 Added 4.3%	30,505 $1.14 Million
Q4 2020 Feb 08, 2021	BUY	$33.66 - $40.76 $17,200 - $20,828	511 Added 1.78%	29,248 $1.19 Million
Q3 2020 Nov 06, 2020	SELL	$33.07 - $38.68 $28,440 - $33,264	-860 Reduced 2.91%	28,737 $1.13 Million
Q2 2020 Aug 07, 2020	BUY	$20.05 - $33.89 $593,419 - $1 Million	29,597 New	29,597 $1 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Cim, LLC, based on Form 13F filings with the SEC.

Stay updated on Cim, LLC with notifications on news.